A61K 49/106
The complex-forming compound being cyclic
Official title: {the complex-forming compound being cyclic, e.g. DOTA}
A61K49/106 (The complex-forming compound being cyclic) appears on 316 US grants and 420 published applications in this corpus.
Search patents in A61K- Granted patents
- 316
- Published applications
- 420
- Assignees
- 206
- Inventors
- 872
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 7 | 0 |
| 1996 | 12 | 0 |
| 1997 | 10 | 0 |
| 1998 | 4 | 0 |
| 1999 | 6 | 0 |
| 2000 | 5 | 0 |
| 2001 | 1 | 0 |
| 2002 | 3 | 8 |
| 2003 | 2 | 5 |
| 2004 | 5 | 13 |
| 2005 | 5 | 10 |
| 2006 | 6 | 8 |
| 2007 | 3 | 12 |
| 2008 | 5 | 10 |
| 2009 | 2 | 13 |
| 2010 | 2 | 8 |
| 2011 | 4 | 10 |
| 2012 | 10 | 7 |
| 2013 | 9 | 11 |
| 2014 | 9 | 23 |
| 2015 | 7 | 14 |
| 2016 | 10 | 29 |
| 2017 | 17 | 23 |
| 2018 | 17 | 20 |
| 2019 | 20 | 22 |
| 2020 | 20 | 39 |
| 2021 | 25 | 28 |
| 2022 | 25 | 31 |
| 2023 | 17 | 24 |
| 2024 | 12 | 20 |
| 2025 | 19 | 21 |
| 2026 | 11 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Manganese-enhanced magnetic resonance imaging29 Sep 2026US 12,745,921 B2Ic Targets AS
- Pharmaceutical compositions of Gd-based contrast agents21 Jul 2026US 12,685,788 B2Bracco Imaging S.P.A.
- CAR peptide for improved coronavirus survival21 Apr 2026US 12,605,455 B2Vascular Biosciences
- Compound and MRI contrast agent containing same31 Mar 2026US 12,589,169 B2Kyungpook National University Industry-Academic Cooperation Foundation
- Process for the preparation of macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetra azacyclododecane-1,4,7-triyl) triacetic acid and it's complexes with paramagnetic metal ions31 Mar 2026US 12,590,073 B2Biophore India Pharmaceuticals PVT. Ltd.
- Long-Lived Gadolinium Based Tumor Targeted Imaging and Therapy Agents8 Oct 2026US 2026/0306634 A1Wisconsin Alumni Research Foundation
- Pharmaceutical compositions of gd-based contrast agents8 Oct 2026US 2026/0306679 A1Bracco Imaging S.P.A.
- Pet/mri contrast agents for in vivo quantification of extracellular acidification13 Aug 2026US 2026/0232848 A1Eberhard Karls Universität Tübingen Medizinische Fakultät Körperschaft des öffentlichen Rechts
- Imaging agents for detecting cd206+ macrophages2 Jul 2026US 2026/0183432 A1The General Hospital Corporation
- Bio-activated reporters to visualize, in real time, specific gene therapy products2 Apr 2026US 2026/0091144 A1Northwestern University
Most cited
By later US patents
- Method of expanded porphyrin-oligonucleotide conjugate synthesis325US 5,565,552 ABoard of Regents, Univ. of Texas Sys. · 1996
- Texaphyrin-oligonucleotide conjugates308US 5,587,371 ABoard of Trustees, Univ. of TX Sys. · 1996
- Texaphyrin metal complexes having improved functionalization254US 5,599,923 ABoard of Regents, University of TX · 1997
- Texaphyrin compounds having improved functionalization233US 5,599,928 ABoard of Regents, The University of Texas System · 1997
- Method of enhancing NMR imaging using chelated paramagnetic ions bound to biomolecules213US 5,021,236 ASchering Corporation · 1991